Early Data With Revumenib Combo Show 100% ORR in Relapsed/Refractory AML
December 9th 2023Results from the phase 1/2 SAVE trial demonstrated an improved objective response rate when revumenib was added to decitabine/cedazuridine, and venetoclax for patients with relapsed/refractory acute myeloid leukemia.
Pembrolizumab Combo Does Not Improve PFS/OS in Advanced/Metastatic TNBC
December 7th 2023Data from the phase 2 KEYLYNK-009 study indicate a lower rate of treatment-related adverse effects with pembrolizumab plus olaparib compared with pembrolizumab plus chemotherapy in those with triple-negative breast cancer.
FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+, HER2– Breast Cancer
November 16th 2023Patients with locally advanced or metastatic breast cancer that is hormone receptor–positive, HER2-negative breast cancer with 1 or more PIK3CA, AKT1, or PTEN alterations may now receive capivasertib plus fulvestrant.
Cabozantinib Combo Does Not Improve Survival in Pretreated, Advanced RCC
June 6th 2023Data from the phase 3 CONTACT-03 trial highlight the necessity of randomized, prospective assessment of re-challenge with checkpoint inhibitors in renal cell carcinoma, according to an expert from Dana-Farber Cancer Institute.
Zolbetuximab/Chemo Up Front Yields Benefit in CLDN18.2+ Advanced Gastric/GEJ Cancer
January 20th 2023Investigators report benefit in patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma treated with first-line zolbetuximab and mFOLFOX6.
PROpel Trial Data Show Boost in Radiographic PFS With Olaparib/Abiraterone for mCRPC
February 19th 2022Results of the phase 3 PROpel trial presented at 2022 ASCO GU indicate a benefit of olaparib-based therapy for patients with metastatic castration-resistant prostate cancer receiving treatment in the frontline setting.
Avelumab Maintenance Yields OS Improvement of First-Line in Advanced Urothelial Cancer
February 18th 2022Frontline avelumab plus best supportive care as maintenance showed an improvement in overall survival vs best supportive care alone in patients with advanced urothelial cancer treated after chemotherapy.